Sorbent Therapeutics Receives $6,500,000 Series D Funding

  • Feed Type
  • Date
    5/15/2014
  • Company Name
    Sorbent Therapeutics
  • Mailing Address
    710 Lakeway Drive Sunnyvale, CA 94085 USA
  • Company Description
    Sorbent Therapeutics is a biopharmaceutical company focused on the development of adaptable non-absorbed polymeric drugs to satisfy unmet clinical needs in large markets such as End Stage Renal Disease (ESRD), Congestive Heart Failure (CHF), Chronic Kidney Disease (CKD), and Hypertension.
  • Website
    http://www.sorbentrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $6,500,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from the financing will be used to support continued development of CLP-1001 and general corporate operations. Sorbent completed the enrollment of 275 patients with heart failure in its Phase 2b STEPWISE clinical trial of CLP-1001, a cross-linked polyelectrolyte polymer intended to selectively bind to and remove excess water and sodium in the GI tract.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor